Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Integrity Applications — AMIZINO Fall 2013 Small Cap / Micro Cap Investment Conference
28 slides from Glucotrack's conference presentation, Oct 29, 2013
Slide 1: Your track to health!... AMIZINO Fall 2013 Investment Conference
Your track to health!... ™ Avner Gal President & CEO October 29, 2013 (OTCQB: IGAP) AMIZINO Fall 2013 Small Cap / Micro Cap Investment Conference Seattle, WA
Slide 2: Disclaimer
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and various provisions of the U.S. Securities Act of 1933, as amended, and the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of h
Slide 3: About Integrity Applications
About Integrity Applications (OTCQB: IGAP) Developing a family of non- invasive glucose monitors for diabetics, to measure their blood glucose level without the pain of drawing blood, and without incremental cost per measurement R&D began in 2001 (Israel); Initial prototype completed in late 2003; M
Slide 4: GlucoTrack Model DF-F
GlucoTrack ® Model DF-F Main Unit (MU) Personal Ear Clip (PEC)
Slide 5: Three independent (non-optical) technologies
Three independent (non-optical) technologies Attempts (by others) to develop non-invasive glucose monitors have mostly been based upon optical technologies, and have not been successful Patented combination of technologies ( simultaneously): ü Ultrasound ü Electromagnetic (Conductivity) ü Thermal (H
Slide 6: GlucoTrack Features & Benefits
GlucoTrack Features & Benefits Easy to operate; User friendly (Just clip it! ™ ) • Clear and simple instructions • Color touch screen • Large digits and Audible result within a minute History graph and list of past 1000 readings Average glucose level calculated displayed Glucose average within desir
Slide 7: “…Like an iPod!” (Prof. Steven Edelman)
“…Like an iPod!” (Prof. Steven Edelman) Just Clip it! ™
Slide 8: GlucoTrack Results
CEG Zone Data Points Percent A 4,309 46% B 4,730 51% C 180 2% D 135 1% E 5 0% Total 100% GlucoTrack Results 36 T1DM; 240 T2DM Body Mass Index (BMI): 33.1+/- 14.2 Kg/m2 Age: 49.5 +/- 31.5 years Clinical trials, conducted by third party, covered virtually the entire demography, including skin colors a
Slide 9: Prevalence of Diabetes: 20-79 Years Old
Prevalence of Diabetes: 20-79 Years Old Source: IDF Diabetes Atlas, 5 th Edition, 2011
Slide 10: Prevalence of Diabetes: 20-79 Years Old (ctnd.)
Prevalence of Diabetes: 20-79 Years Old (ctnd.)
Slide 11: Advances in Blood Glucose Monitoring
Advances in Blood Glucose Monitoring A strip of paper changes its color according to the patient’s glucose level Meter interprets more accurately the light reflected by a color on the meter into a readable number Glucometer (Bayer) becomes the first home glucose monitoring device FDA, CDC and ADA di
Slide 12: Advances in Blood Glucose Monitoring
Advances in Blood Glucose Monitoring GlucoTrack model DF-F, a truly non-invasive glucose monitor, has gained CE Mark approval June 2013
Slide 13: Importance of SMBG is Recognized!
Importance of SMBG is Recognized!
Slide 14: HbA1c as a Function of SMBG
HbA1c as a Function of SMBG HbA1c as a function of SMBG measurements per day (Source: Diabetes Atlas, 2 nd edition, 2003) ADA (June 2012): Reducing HbA1c a Little Less than 1 Point Reduces CV Risk by 45%
Slide 15: Yet Significant Barriers Exist
Yet Significant Barriers Exist Prick the fingertip (ouch…) Draw blood, infuse drop onto a test strip Painful; Expensive
Slide 16: Compelling Economics
Compelling Economics Assumptions: Invasive measurement costs $1.00 each; Retail price for GlucoTrack DF-F: $2,000 (including one PEC); PEC costs $100; replaced every 6 months; Excludes re-calibration costs, which are expected to be approximately $70, in total, over a five year period.
Slide 17: If you owned a non-invasive glucose monitor, which requires no disposables, would you:
If you owned a non-invasive glucose monitor, which requires no disposables, would you: 96% (8) Measure yourself A much more often 145% (12) Keep your current BM rate of measurements seem [Novease the measurements! ‘frequency a litle IE Don't know TA % (59) 48% (4)
Slide 18: Market volume
Market volume Source: Kalorama Information Diabetes and Diabetic Complications March 2007 Self Monitoring of Blood Glucose Market was estimated as $8B In 2010 Source: Pharmalive.com, May 2010
Slide 19: Recent Achievements; Anticipated Actions
Recent Achievements; Anticipated Actions Improving the device ü Smaller version of Personal Ear Clip (PEC) - enables use by people with smaller ear lobes (awaiting clinical trials); ü PMCF: collecting data to enable algorithms’ improvement; ü Embedding state of the art Anti-cloning & Encryption (H/W
Slide 20: Recent Achievements; Anticipated Actions
Recent Achievements; Anticipated Actions Preparation for mass production manufacturing ü Audited potential manufacturers (Israel, China, Taiwan, Philippines); ü Finalization of Main Unit (MU) mold (E/O December); ü Design & build tools & testers for MU (E/O December); ü Finalization of PEC mold (E/O
Slide 21: Recent Achievements; Anticipated Actions
Recent Achievements; Anticipated Actions Marketing & Sales Activities ü Booth in EASD Conference (September); ü Table in Medica, Dusseldorf, Germany (November); ü On going participation in conferences (posters; presentations); ü Launched a redesigned website (October); ü Meetings with Key Opinion Le
Slide 22: Recent Achievements; Anticipated Actions
Recent Achievements; Anticipated Actions Regulatory & Other Activities ü Clinical pilot in South Africa (November); ü Clinical trials for minors, 6-18 years old (E/O Q1/14); ü Submission of 6 months trial’s results (Approval expected E/O Feb.); ü Preparation for FDA clinical pathway (with NAMSA); ü
Slide 23: Products Road Map
Products Road Map DF- B : B asic model for use in developing countries DF- C : C ontinuous monitoring of glucose level DF- N : Provides N ight time advanced warning of hypoglycemic episodes DF- D : Warns D rivers of low glucose level DF- I : System for pediatric I ncubators DF- P : Device for (IGT)
Slide 24: Competitive Landscape
# Company Product Technology Calibration Measurement Picture Comments 1 Echo Therapeutics (MA, USA) Symphony Ultra Sound (ISF) 12 hours between calibrations Continuous For ICU; In clinical trials 2 Grove Instruments (MA, USA) Gi-200 Optical Bridge No data Spot In clinical trials 3 Cnoga Medical (Isr
Slide 25: Management
Management Avner Gal: President & CEO, Chairman (Co-Founder) Retired Naval Commander, strong Engineering & Management background David Malka: Executive VP & COO (Co-Founder) Rich experience in Operations, including founding Operation Departments Kobi Bar-Shalom: CFO Rich experience in different size
Slide 26: Medical Advisory Board
Medical Advisory Board Dr. Ilana Harman-Bohem, MD Manager of Diabetic department at Soroka University Medical Center Prof. Yariv Malimovka, MD Senior consultant to Spanish medical centers in blood vessels & surgery Adi Ickowicz / MedicSense (Regulatory affairs) Rich experience in medical devices are
Slide 27: Capitalization
Capitalization Approximately 5.14 million shares of common stock outstanding (October 7, 2013); Approximately 472,000 shares of the Company’s common stock are issuable upon exercise of outstanding stock options; Approximately 1.57 million shares of common stock are issuable upon exercise of outstand
Slide 28: Thank You!
Your track to health!... ™ Thank You! www.integrity-app.com
Integrity Applications — AMIZINO Fall 2013 Small Cap / Micro Cap Investment Conference on 6ix